Fatigue — Persistent exhaustion linked to cancer

Cancer-related fatigue is defined clinically as a distressing, persistent, subjective sense of physical, emotional, or cognitive tiredness related to cancer or its treatment. It is disproportionate to recent physical activity and interferes significantly with normal daily functioning. Unlike regular tiredness following exertion, cancer fatigue tends to linger for weeks, months, or even years after treatment concludes.

Biologically, this condition is multifactorial, arising from chronic systemic inflammation, endocrine disruption, metabolic alterations, anaemia, and disruptions to the circadian rhythm. Cytokines released by tumour cells or triggered by therapeutic interventions cause neurochemical changes in the brain that promote lethargy and cognitive blunting. It can affect physical stamina, mood, motivation, and memory.

Recognising and discussing fatigue is vital because unmanaged fatigue reduces quality of life, limits independence, and may lead to missed doses or early discontinuation of life-extending therapies. When patients share their exhaustion levels, clinicians can screen for treatable secondary causes such as severe anaemia, thyroid failure, sleep apnoea, malnutrition, or uncontrolled pain. Managing fatigue allows patients to remain active, tolerate treatments better, and maintain important social connections. Addressing it proactively helps protect both physical independence and emotional well-being throughout the care pathway.

Fatigue itself cannot be identified through a single laboratory test; instead, doctors measure its severity using validated questionnaires such as the Brief Fatigue Inventory or visual numerical scales. Clinicians perform diagnostic blood tests to exclude physiological drivers. These investigations routinely include a full blood count to identify anaemia, serum ferritin to assess iron reserves, comprehensive metabolic profiles to detect electrolyte imbalances, and thyroid function tests to exclude hypothyroidism.

Cancer-related fatigue affects individuals across virtually all malignant diseases. It is especially prevalent in haematological cancers such as leukaemia, lymphoma, and multiple myeloma due to bone marrow disruption. High rates are also documented in solid tumours, including advanced breast cancer, lung cancer, colorectal cancer, prostate cancer, and ovarian cancer. Patients undergoing multi-modal therapy—such as concurrent chemoradiotherapy—consistently report the highest intensity and duration of fatigue symptoms.

The presence of severe fatigue influences treatment scheduling, dose intensity, and supportive interventions. Clinical teams may prescribe blood transfusions or erythropoiesis-stimulating agents if anaemia is present. Evidence strongly supports structured, tailored aerobic exercise programmes, energy conservation training, cognitive behavioural therapy, and nutritional counselling. In select advanced cases, clinicians may evaluate temporary psychostimulants or corticosteroid therapy to help preserve functional performance during critical treatment phases.